17 1 Table 2. CINV prophylaxis recommendations for MEC regimens. MEC regimen type Recommendations ASCO (2017) MASCC/ESMO (2016) Carboplatin AUC ≥4 (mg/mL)/min Acute Delayed Carboplatin AUC <4 (mg/mL)/min or non-carboplati Acute Delayed 5-HT3 RA + NK1 RA + DEX AQE: high ASR: strong No prophylaxis QE: high ASR: strong 5-HT3 RA + DEX AQE: high ASR: strong No prophylaxis; DEX for agents known to cause delayed CINV AQE: low ASR: moderate 5-HT3 RA + NK1 RA + DEX MLCO: moderate; MLCS: moderate ELE: II; EGR: B No prophylaxis; APR if APR used in acute MLCO: moderate; MLCS: moderate ELE: III; EGR: B 5-HT3 RA + DEX MLCO: moderate; MLCS: moderate ELE: II; EGR: B No prophylaxis (a); DEX (b) for agents known to cause delayed CINV (a) MLCO: no confidence possible; MLCS: high ELE: IV; EGR: D (b) MLCO: low; MLCS: moderate ELE III; EGR: C Abbreviations: APR, aprepitant; AQE, ASCO quality of evidence; ASCO, American Society of Clinical Oncology; ASR, ASCO strenght of recommendation; AUC, area under the curve; DEX, dexamethasone; ELE ESMO level of evidence; EGR, ESMO grade of recommendation; MASCC/ESMO, Multinational Association of Supportive Care in Cancer/European Society of Medical Oncology; MEC, moderately emetogenic chemotherapy; MLCO, MASCC level of confidence; MLCS, MASCC level of consensus; NK1 RA, neurokinin-1 receptor antagonist; 5-HT3 RA, serotonergic receptor antagonist.
RkJQdWJsaXNoZXIy MjY0ODMw